The AIM-listed data analytics company has been awarded a contract to provide imaging services for Vaccinex’s planned phase Ib/IIa trial for its pepinemab as an Alzheimer’s treatment.
Ixico already is supporting the US immunotherapy company’s SIGNAL trial by providing imaging services Phase II study of pepinemab as a treatment for Huntington's disease.
The company’s digital platform and artificial intelligence (AI) software manages and helps interpret images from magnetic resonance imaging (MRI) and other scanners.
“This AD trial, called SIGNAL-AD, is part of a new wave of investment in treatments for neurodegeneration by the global biopharmaceutical industry, with additional assets being brought through the pipeline thanks to the insights unlocked in earlier research programmes,” said Giulio Cerroni, chief executive of Ixico.
In the existing project with Vaccinex in Huntington's disease, Cerroni said the positive imaging results obtained in an interim cohort analysis indicated its potential in additional therapeutic areas.
After the previous contract was initiated in 2017, he said the new award “is a great testament to the achievements of our two organisations working diligently together since then”.
Last month, Ixico joined the Alzheimer's Disease Neuroimaging Initiative (ADNI), with two of the company's scientists joining the private partner scientific board of ADNI, which is a longitudinal multicentre study looking to develop clinical, imaging, genetic and biochemical biomarkers for the early detection and tracking of Alzheimer's disease.